Not Yet RecruitingNot Applicable

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

100 participantsStarted 2026-02-01

Plain-language summary

AU-011-403 is a multicenter long-term follow-up safety and efficacy study of subjects with early CM who previously participated in the AU-011-301 Phase 3 trial. There are no required interventions or use of AU-011 (bel-sar) in this long-term follow-up study

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Have received bel-sar or sham treatment in the Aura-sponsored clinical trial AU-011-301. * Be willing and able to consent to the AU-011-403 study. Exclusion Criteria: * None

What they're measuring

Incidence of adverse events (AEs)/serious AEs.

Timeframe: 5 years

Trial details

NCT IDNCT07338968

SponsorAura Biosciences

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2033-08-15

Contact for this trial

Medical Monitor

617-500-8864 clinical@aurabiosciences.com

View on ClinicalTrials.gov More Choroidal Melanoma trials